Abiraterone and Enzalutamide for mCRPC
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
Clinical Pearls
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
- The phase III PREVAIL study looked at enzalutamide versus placebo in chemotherapy-naïve, asymptomatic patients with metastatic castration-resistant prostate cancer
- There was a statistically significant survival benefit and positive prolongation of radiographic progression-free survival in favor of enzalutamide
- Dr. Ryan believes these data will drive the eventual use of this therapy in the chemotherapy-naïve population
- Physician prescribing preferences will ultimately determine how abiraterone and enzalutamide are used
<<<
Isatuximab Plus VRd Enhances MRD Negativity and Responses in Transplant-Ineligible NDMM
December 10th 2024The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma.
Read More
